Last reviewed · How we verify
iodinated contrast agent
At a glance
| Generic name | iodinated contrast agent |
|---|---|
| Also known as | Iodinated Contrast Dye, Iodine-containing Contrast Media |
| Sponsor | Bracco Diagnostics, Inc |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Acute Kidney Injury in Patients Undergoing Contrast Exposure: VQ vs. CT (NA)
- A Contrast Medium Sparing Strategy Using Automated CO2 Injection During PVI for Prevention of Major Adverse Kidney Events (MAKE) (PHASE3)
- qDSA Blood Flow Measurement in Patients Undergoing TAE of the Liver (NA)
- Achilles Tendinopathy Embolization (PHASE1)
- Ultra-low Dose Contrast for Endovascular Procedures
- TAVR for Aortic Regurgitation Under TTE Guidance (NA)
- "Detection and Follow-up of Coronary Lesions in HeFH (DESTINY-FH Study)" (NA)
- 1-hour Premedication for Allergy Goal in Emergency: PAGE-1 Study (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- iodinated contrast agent CI brief — competitive landscape report
- iodinated contrast agent updates RSS · CI watch RSS
- Bracco Diagnostics, Inc portfolio CI